Coherus Oncology, Inc. (CHRS) Earnings Call Transcript
November 6, 2025
Earnings Call Speaker Segments
Thanks, Heidi. Good afternoon, and welcome to Coherus Oncology's third quarter 2025 earnings conference call. With me today to talk about our results are Denny Lanfear, our Chief Executive Officer; Bryan McMichael, Chief Financial Officer; Dr. Rosh Dias, Chief Medical Officer; Dr. Theresa LaVallee, Chief Scientific and Development Officer; and Sameer Goregaoker, Chief Commercial Officer. Before we begin, I want to remind everyone that this call contains forward-looking statements about Coherus' current expectations regarding future events. Actual results could differ materially, and we assume no obligation to update or revise any forward-looking statements. For additional detail on risks and uncertainties, please refer to the press release we issued today and our quarterly report on Form 10-Q. I'll now hand the call over to Denny.
Thanks, Carrie, and good afternoon, all, and welcome to our earnings call for Q3 2025. Before we begin, I'd like to welcome Arvind Sood to Coherus Oncology, who has just been named our Chief Strategy and Corporate Affairs Officer. Arvind's duties cover investor relations, corporate development, and government affairs. Arvind, welcome.
Thank you.
We're in a really good place, and I'm thrilled today to walk you through how our strategic plan has advanced over the most recent quarter, plus give you a broader look back at what we've accomplished during the year now that 2025 is nearly behind us. As you're aware, executing well is something we take a lot of pride in, and on every front that execution has been solid. To illustrate, you might remember that when I spoke with you a year ago, I laid out goals that included growing the top line, cutting costs, and making the balance sheet stronger. I'm happy to report that we've made significant progress on each of those three areas. We're particularly pleased with the advances we've achieved regarding the balance sheet and our expenses, which are substantial improvements compared with where we stood twelve months ago. Bryan McMichael, who serves as our Chief Financial Officer, will walk everyone through those results personally. Turning to what the Coherus Oncology story offers investors, it comes down entirely to our medicines, the data as it keeps developing, and the chance to strike deals. A solid approach has set us up to win, and we've generated real momentum while hitting our stride. When it comes to our drug portfolio, LOQTORZI is a next-gen PD-1 that works in cancers with low PD-L1 expression and has received approval for nasopharyngeal cancer — an area where it brings in money for the company, with sales and margin contributions that keep growing. Our Chief Commercial Officer, Sameer Goregaoker, is going to walk through the specifics and details on that shortly, and he'll reaffirm how confident we are in reaching our revenue goals. As a cancer-focused company, what drives us is making a dramatic leap forward in how long patients survive. That's our goal. In our view, the future of helping patients live longer depends on combinations, and we're combining LOQTORZI with our own proprietary pipeline assets across a range of indications. There's another way LOQTORZI gets used too — alongside therapeutic assets that belong to other companies. If any of those drugs get approved, that becomes a revenue multiplier, which is the second key role it plays in our strategy. Right now, we're going after liver and lung cancer with casdozokitug, and also with CHS-114. With our CCR8 Treg depleter, the targets are head and neck cancer, gastric cancer, esophageal, and as of now colorectal cancer — an area where we've expanded our focus — and every one of these is paired with LOQTORZI. That leads me to the second item investors should keep in mind: our data. In just a moment, Dr. Our Chief Medical Officer, Rosh Dias, is going to give you a fuller picture on where we stand with enrollment and our clinical trials. What I'll say at this point is that every study we've started is now actively enrolling, and we're doing this worldwide. Nearly all of our sites are up and running as we push toward bringing you data next year in these indications that look so promising. On the clinical development side, we've really found our rhythm. The investigators we're working with are deeply committed and excited about these mechanisms of action, which hold a great deal of promise, and they're getting their patients signed up, drawing on that urgent unmet need to halt their cancers. Dr. Our Chief Scientific and Development Officer, Theresa LaVallee, will spend a few minutes with all of you today walking through the mechanism behind our drugs, with particular emphasis on the therapeutic opportunity created by going after T regulatory cells. As everyone on this call knows, this field earned a Nobel Prize in Physiology or Medicine not long ago, bringing it widespread attention and making clear its potential as a treatment approach. Coherus Oncology, a frontrunner in this rapidly advancing area, is proud to have been the first to demonstrate Treg depletion together with the CD8-positive T cell infiltration that followed in a patient. We were invited by the organizers of the 2025 SITC meeting to share our data during a recent webinar, and that session drew the largest audience of the year. Our CHS-114, a highly selective CCR8 Treg depleter, has the potential to be best in class. Because Tregs are widely distributed throughout the body and play such a significant role, selectivity becomes the dominant factor; with our broad yet focused clinical program producing results across 2026, we are positioned well to carry forward the scientific leadership we showed in 2025. CHS-114 and casdozokitug are both ours on a worldwide basis, and I'd like to share a few views about possible deals — the third piece of the value story that investors should keep in mind. From a mechanistic angle, getting rid of Tregs could work well alongside a wide variety of medicines already on the market, because when T regulatory cells are present at higher proportions and greater density, results for patients tend to be worse. Recall my earlier comments about combinations; the implication is that pairing something like CHS-114 with ADCs, bispecifics, or radiation treatment, or with other therapeutic approaches, might lead to better outcomes and longer survival. We're pursuing those partnership chances both within the United States, which is where our commercial attention is directed, and around the world beyond the U.S., a territory where we haven't yet concentrated but where we still retain complete rights. Deals along these lines would bring us money from upfront payments that helps cover our continuing clinical development expenses, and what matters even more, they'd supply contributions to the cost of pivotal or registrational trials, which have to be conducted on a global basis. Over the coming six, 12, and 18 months, we expect our maturing clinical data to generate arrangements of this sort, and we'll continue to keep everyone informed during our calls. Having said that, I'll hand it over to Theresa. Dr. LaVallee?
Thanks, Denny, and good afternoon. It's great to share an update on the innovative pipeline at Coherus Oncology, which is focused on moving cancer treatments forward. I'll begin with this year's Nobel Prize in Physiology or Medicine, which acknowledged how important T regulatory cells and immune homeostasis are. When Tregs don't work properly or aren't there at all, the result is serious autoimmune disease, which offers strong proof of the essential function these cells serve in peripheral immune tolerance. Tumors take advantage of these cells as a main way to escape the immune system. That's a problem, since it leads to cancer growing and progressing. It's established that Tregs found in tumors correlate with poor outcomes for any cancer therapy, whether chemotherapy, radiation, or, naturally, PD-1 inhibitors. Although this is well understood, the field has struggled to find a method to selectively hit Tregs inside the tumor while leaving those in peripheral tissue alone. CCR8 is a protein that is preferentially expressed on Tregs residing in tumors, which makes a targeted therapy approach possible to selectively eliminate these immune suppressants within the tumor; we've concentrated on CCR8 as a drug target for multiple years and think our program stands apart from others in the field. CHS-114 is a cytolytic antibody featuring ADCC enhancement. It's built to locate and destroy CCR8-positive Tregs. This mechanism resembles that of an ADC molecule, and here the payload is enhanced effector function that causes Treg killing. Our preclinical and clinical findings have demonstrated differentiation, potency, and tumor response. CHS-114 underwent assessment for binding against more than 5,000 human proteins, the full proteome accessible on the cell's exterior. Notably, CHS-114 binds to just one protein, its target, CCR8. Getting rid of off-target binding could potentially yield a differentiated safety profile. CHS-114 is the sole selective CCR8 antibody currently known. In addition, it has demonstrated an acceptable safety profile, selective depletion of CCR8 Tregs in tumors, and also a striking capacity to bring about an increase of CD8 T cells within tumors, thereby characterizing the tumors as hot or immunologically responsive. In the initial safety cohort of seven U.S. patients evaluating CHS-114 alongside toripalimab, a response was seen in a fourth-line head and neck cancer patient. All of these data not only demonstrate that the idea works. Targeting CCR8 will primarily eliminate tumor Tregs, but also show that treatment with CHS-114 remodels the tumor to become more immune active. This weekend at the annual SITC conference, we'll present additional biomarker data showing significantly enhanced immune activation in head and neck cancer patients following CHS-114 treatment with toripalimab. This matters because we are testing whether combinations of CHS-114 with toripalimab can overcome PD-1 resistance in refractory patients. The pharmacological and clinical attributes of CHS-114 establish it as having good drug-like properties, and this pairs with our program's focus on generating data to address two areas of increased scrutiny by the U.S. FDA. First, data in a Western population, and second, dose optimization. Establish our scientific leadership in the space. My final remark regarding CHS-114 concerns its nature as a targeted treatment. Essentially, we can identify which patients should receive it: those whose tumors show a high prevalence of CCR8, the target it acts upon. Among the tumor types featuring elevated CCR8 are lung, colon, head and neck, and gastric, among others. Coherus Oncology is giving priority to certain of these cancers and has begun enrolling a fresh cohort testing CHS-114 alongside toripalimab in a patient group that currently has no approved immunotherapy. That is microsatellite stable colorectal cancer. This clinical program is built to produce data across multiple solid tumors and to further clarify where CHS-114 plus toripalimab yields meaningful clinical benefit either by itself or combined with chemotherapy; now, shifting to our next promising clinical program, casdozokitug. A different strategy for getting past immune evasion involves activating NK cells. The body's immune killer cells consist of T cells and NK cells. Casdozokitug, the first-in-class IL-27 antagonist from Coherus Oncology, produces immune activation of T cells as well as NK cells. During this week's International Cytokine and Interferon Society meeting, we shared preclinical and clinical biomarker data demonstrating a significant role for NK cell activation and for casdozokitug's efficacy, especially in first-line HCC, a tumor type abundant in NK cells. The refreshed biomarker data kept supporting the idea that casdozokitug treatment brings about inhibition of IL-27 signaling and heightened cytolytic immune activity from NK and T cells. What makes this matter? There are 2 reasons. First, casdozokitug treatment produces robust NK cell activation. This may offer a mechanistic account of why the results revealed more than a doubling of the complete response rate. Turning on both NK and T cells might maximize tumor cell killing and cause its disappearance. The second reason I emphasize this is that whenever a new drug gets added to standard of care, we must demonstrate the contribution of components, or put simply, whether casdozokitug adds anything to standard of care; these data increase our confidence that the deepening of response is tied to casdozokitug treatment, given that patients who respond display IL-27 inhibition and substantial NK cell activation. Additionally, I want to restate Denny's remarks that finding partnerships which speed up pipeline development is a priority. We hold global rights to casdozokitug and CHS-114 alike, and these compelling clinical data across the 2 pipeline assets are underpinning talks with prospective partners. Before handing things to Rosh, allow me to briefly recap why recent developments with our key pipeline molecules excite us; we were delighted that the Nobel Prize in Physiology or Medicine acknowledges the significance of T regulatory cells in immune homeostasis. At the SITC meeting this week, we will present biomarker data revealing enhanced immune activation among head and neck cancer patients after treatment with CHS-114 combined with toripalimab. Furthermore, our presentation of biomarker data earlier this week at the International Cytokine meeting offers added support for casdozokitug's contribution on top of standard of care in liver cancer patients. With that, I will pass it to Dr. Dias will provide additional details about the clinical development.
Thanks, Theresa, and good afternoon to all of you. Because there's a definite unmet medical need and the possibility of doing better than currently available treatments, we're pushing our casdozokitug and CHS-114 programs forward aggressively in the indications we've chosen to focus on. Investigators around the world stay strongly engaged with, and enthusiastic about, both molecules, taking part very actively in our trials. Let's begin with casdozokitug in first-line hepatocellular carcinoma. Our trial now running is multinational, has three arms, and randomizes patients between two dose levels of casdozokitug plus toripalimab, toripalimab by itself, and toripalimab on its own, with three objectives built into its design. The first is efficacy and safety data. Next, there's meeting the requirements of the FDA's Project Optimus. Then, we're working on demonstrating how each component contributes as we move forward through development. Just to recap, this study is built on the highly promising results we presented at ASCO GI earlier this year in January. In trial 201, the combination of casdozo with the TZO and bev yielded a 38% overall response rate, along with a 17% complete response rate—results that showed improvement in ORR and greater depth of response compared with the earlier data from the same study. These figures also compare favorably to historical benchmarks for the TZO and bev alone, which were 30% for ORR and 8% for CR. Given these encouraging findings, investigators worldwide have shown strong enthusiasm regarding what the casdozo/torip/bev regimen could offer. Enrollment for this trial has reached its target, and we expect to remain on schedule to report initial efficacy and safety data during the first half of 2026. Now we'll turn to CHS-114, the cytolytic antibody we've developed that targets CCR8. Because of what we know about CCR8 biology, this agent could be useful across many different tumor types, and our strategy focuses narrowly on four specific tumors where the biological and clinical justification for testing is especially strong. The first of these is second-line head and neck squamous cell carcinoma. At AACR earlier in the year, we described a partial response accompanied by substantial tumor reduction in a patient receiving fourth-line treatment. Notably, this individual had not responded to several earlier therapies, among them a PD-1 agent, a TKI, and a taxane. A few weeks back, we were asked to present this data once more at a SITC seminar, which Denny noted drew the largest audience of any session in the SITC webinar series. Enrollment is moving forward as designed in our continuing trial that is examining a pair of CHS-114 dose levels given alongsidethecombinationagent,within the second-line head and neck squamous cell group whose disease has not responded to earlier PD-1 treatment, and we remain on schedule to share both efficacy and safety findings during the first half of 2026. Those results will help us understand how much CCR8 matters as a resistance pathway specifically in second-line head and neck squamous cells. Turning to second-line upper GI adenocarcinoma, which takes in a second-line gastric, GEJ, and esophageal adenocarcinoma population that has stopped responding to one earlier line of therapy, we are likewise testing two CHS-114 dose levels in combination withthecombinationagent.To remind everyone, second-line gastric cancer represents a setting in which mechanism proof has previously been demonstrated using the CCR8 class together with. Enrollment is proceeding according to plan, and we remain on schedule to share efficacy results during 2026's second half. Third, esophageal squamous cell carcinoma is another area we're going after. This leverages tori's activity regardless of PD-L1 levels, and we are examining both first-line and second-line settings, where substantial medical need persists; within the second-line group, we are conducting limited dose expansion of CHS-114 plus tori, while our first-line cohort functions as a safety cohort intended to collect data on CHS-114 combined with tori and standard chemotherapy. On this front as well, we remain on schedule to share efficacy results during 2026's second half. Fourth, as Denny mentioned previously, the CHS-114 program now includes a colorectal carcinoma arm; beyond a significant unmet medical need, this tumor type carries a compelling supportive biological rationale, since CCR8-positive Tregs show elevated prevalence and density in CRC. Our CRC strategy seeks to investigate combining CHS-114 and tori, starting with a fourth-line plus MSS group, where today's late-line standard of care delivers a mid-single-digit ORR and patients genuinely require more therapeutic choices. Our trial examines the combination first in the non-liver mets group and will advance rapidly into the liver mets group, which has historically shown greater resistance to available therapies. We feel a lot of energy around how our clinical programs are moving forward, since our goal is to deliver better options to patients fighting cancer who need them, and we're eager to reveal results from several studies over the course of 2026; at this point, I'll hand the discussion to Sameer. Sameer?
Thank you, Rosh. I'll organize my remarks today around three topics. To start, I'll walk through how LOQTORZI performed commercially in Q3. After that, I'll talk about how the market is shifting, particularly when it comes to community practices versus academic centers. And third, I'll lay out what we intend to do to keep growth going next quarter. LOQTORZI's net revenue for Q3 climbed to $11.2 million, which represents a 12% sequential gain and a 92% jump compared with the same period a year ago. That said, it marks a slowdown from the 35% expansion recorded in Q2. Let me put that into some perspective. The Q2 figure benefited from inventory rebuilding after stock levels had run low. Underlying demand rose roughly 20% during that quarter. By contrast, Q3 saw inventory hold steady, meaning essentially all of our gains were attributable to end customer demand. It's worth noting that our sales force is organized into four territories nationwide. This quarter, three of those four territories averaged 21% growth, which is fairly close to what we saw in Q2. But the fourth territory posted no growth, a consequence of vacancies that arose after restructuring, which reduced share of voice and dragged down the national average. That problem has since been resolved, and shortly I'll get into why reinforcing a consistent method across our customer base matters so much, along with the steps we're taking. This quarter's expansion came from new patients starting treatment in both newly added and pre-existing accounts, plus longer treatment durations. The overall count of accounts buying LOQTORZI rose by more than 15%, a sign that usage is broadening. On top of that, 30% of existing accounts have now prescribed LOQTORZI for a later patient, which speaks to strong physician satisfaction. Looking further ahead, we aim to capture a dominant share of the NPC market, which we estimate sits somewhere between $150-$200 million. That implies average demand growth of 10%-15% over the coming three years, keeping us on pace to hit our long-term objectives. Let me turn now to market dynamics. As you're aware, roughly 2,000 patients a year are eligible for LOQTORZI. Both hospital-based head and neck specialists and community physicians treat these patients. That said, these two groups differ in important ways, and we need to account for that if we want a dominant share in each. To begin with, hospital-based head and neck specialists treat multiple NPC patients annually and have solid familiarity with the NCCN guidelines and our clinical data. Within this segment, LOQTORZI is growing strongly, both at NCCN institutions and across other large hospital systems. Because of this, we're redirecting our efforts away from brand awareness and toward identifying new patients and building advocacy from academic care wells. In our second segment, the community, things look quite different. The main reason is that community physicians juggle many tumor types at once, so a rare disease like NPC isn't always front of mind. The addressable opportunity across the community is spread very thinly, and physicians generally encounter just one to two new NPC patients annually. Because of this, there isn't much awareness out there regarding our favorable positioning in the NCCN guidelines or the data showing our clinical superiority. Treatment with chemotherapy by itself, or off-label IO, is still hanging around. What lies ahead for us is quite evident. In the community, we need to keep hammering home our clinical narrative. Following the divestiture, we have a reduced sales force, so our reach and our share of voice have been constrained, especially in the lagging region we observed during this quarter. Against that backdrop, I'd like to walk you through a plan with 3 points aimed at generating community growth. To start, we are growing our sales force by roughly 15%, which will boost our reach in certain geographies. This expansion is highly targeted; we consider it financially prudent and expect it to yield a positive ROI. Next, we are bringing on a remote sales team whose job is to spark engagement with oncologists whom sales representatives aren't managing to reach. Reaching these physicians in a manner that keeps costs down will take our reach further into the community. Third, we are substantially growing our multi-channel abilities so we can educate physicians in the community. To be specific, we're putting together a campaign made up of KOL-driven digital programs that are highly engaging. Our field team, our website, and third-party distributors will all be involved in distributing them. To sum up, we foresee considerable growth possibilities for LOQTORZI over the quarters ahead; in promotional effectiveness research we carried out recently, physicians reported that our overall survival messaging and the NCCN guidelines resonated strongly with them; we stay confident that executing with focus will produce robust demand growth, and we are on course to hit our long-term commercial objectives. Having said that, I'll hand the call over now to our Chief Financial Officer, Bryan McMichael.
Thanks, Sameer, and good afternoon to all of you. Following over a year of deal-making, the third quarter of 2025 marked our first complete quarter after leaving the biosimilar sector behind; the money from that divestiture went toward clearing every near-term maturing debt, and we've now become an innovative organization focused entirely on novel oncology. Today I'd like to offer some key observations regarding where the company stands as Q3 closes and we move toward the end of the year and the data readouts coming next year. To begin, our balance sheet looks considerably stronger than it did at last year's close. Cash plus investments totaled $192 million when Q3 ended. Out of $429 million in overall liabilities on the quarter-end balance sheet, over half — $254 million — was tied to transition service agreements; those obligations will be resolved through reimbursements from the buyers in the divestitures or cash gathered directly from their customers. The non-TSA share of liabilities that remains fell 69% from last year's end. By the close of Q3, we had managed to transfer or wind down most of the Edenica-related operations, streamlining Coherus so we can concentrate more on the priorities Denny laid out, specifically expanding LOQTORZI sales and advancing our pipeline. We're on track to reach fewer than 140 FTEs around year-end. That's a revision from the earlier guidance of 150 FTEs. Today I'll keep my review of the results to the key updates. Detailed quarterly results and figures are available in our earnings press release. As Sameer explained thoroughly, rising LOQTORZI volumes fueled gains in net revenues from continuing operations for both the quarter and the year-to-date periods. Our continuing operations show solid execution against our strategy, beginning with OPEX. R&D expenses came to $27.3 million for the quarter, a 24% increase over Q3 of last year. That rise stemmed from pipeline investments and was partly offset by savings from programs we deprioritized during the past year. SG&A expenses reached $24.9 million for the quarter, an 11% decline versus last year, mainly because of lower headcount. Keep in mind, these numbers cover continuing operations. Total OPEX tied to discontinued operations, which reflects the biosimilar business, shrank to under $1 million in Q3 2025. To give a sense of the savings from the divestitures, OPEX for discontinued operations across FY 2024 came to over $40 million; for the full year 2025, we are reaffirming our forecast that SG&A expense from continuing operations will land between $90-$100 million. That range covers costs incurred purely for Coherus programs and leaves out non-reimbursed TSA costs along with asset impairment charges. Before I return the call to Denny, allow me to sum up the progress achieved since Coherus was transformed into the innovative oncology company it is now. Three points stand out. First, we've strengthened our balance sheet by cutting liabilities substantially while keeping enough cash, which we anticipate will fund operations through 2026 and past the key data readouts next year. Next, our approach to boosting LOQTORZI revenue involves putting focused resources into the commercial setup so we can achieve expansion in upcoming quarters and years. Also, we've shown restraint with our spending, making our operations more efficient—this includes reduced SG&A costs and targeted R&D funding aimed at our pipeline candidates, CHS-114 and casdozokitug. With $90 million in savings, I'll now return the call to Denny.
Thanks, Bryan. I'd like to walk you through where we stand after this quarter during the minute we're taking into Q4, and explain the reasons for our enthusiasm. First off, we delivered solid execution everywhere, across every key area of the business and its disciplines. Financially, we grew the top line through greater LOQTORZI sales, all while bringing overall costs down and making the balance sheet stronger, which Bryan just covered. We moved the pipeline forward, as Rosh discussed. With clinical trials pairing LOQTORZI and our own proprietary assets continuing to advance, we got ready to reveal key data cards next year covering more than 6 studies. Importantly, holding full global rights to our pipeline products at this stage of the company's evolution opens up partnering opportunities outside the U.S., and those will act as currency to offset ongoing clinical development costs all the way through approval. Finally, let me take a moment to thank every one of our dedicated team members at Coherus Oncology for their remarkable commitment to the company and their strong performance as we strive to create value for patients and for shareholders. Heidi, we're ready for the questions.
Hello, and thanks for taking my question. I've got one thing I'd like to ask, and it leans toward the R&D side; it appears the CCR8 mechanism might be complemented not only by anti-PD-1, but possibly by having both targets on a single molecule in a bispecific format. I'm wondering whether that makes biologic sense, and if it does, whether you've looked into that possibility at all. Thank you.
Hi, Mike, and thanks for asking. Dr. LaVallee would be glad to share a bit more perspective on that with you. Theresa.
Hello, Mike. I appreciate it. To put it another way, are you referring to creating a molecule that goes after CCR8 and an additional target?
Correct. And possibly anti-PD-1 or PD-1.
Yes, so what makes that difficult — I mean, bispecifics are getting attention — but since the mechanism here works by binding and killing, my view is this: attempting to eliminate the Treg cell while also blocking PD-1 on a cytotoxic T cell would be quite hard. Some groups are developing bispecifics against CCR8, yet what appears truly encouraging about treatment with CHS-114 isn't just the pronounced depletion of Tregs — those immunosuppressive Tregs within the tumor — it's also drawing the CD8s in. My sense is that a more conventional combination strategy, exploring other routes to immune activation, would likely produce — I mean, grounded in scientific hypothesis, would produce — a more robust clinical response. There are people pursuing CCR8 bispecifics, so we'll need to monitor how those data come out.
Thanks, Mike.
Hi, everyone. Appreciate you letting us ask a few things this afternoon. So, starting with LOQTORZI, perhaps. What's our view of how things are trending now? At what point do you expect the next step-up? If you extend the line from where we stand now toward that goal, I believe it was $150 million-$200 million in peak sales by mid-2028, what shape do you expect that path to take? And where's the biggest bottleneck at present, in your view? I've got one short follow-up. Thanks.
Yes, appreciate the question, Brian. I'll take that one first, then we'll move on to the follow-up. Let me try to get this right, or else I'll pass it to Sameer. To begin with, Sameer laid out that if you simply start from where we are now and extrapolate a straight line of 10%-15% each quarter, you wind up in the target zone of $150 million-$200 million around mid-2028-ish. That's roughly the reference point, though I'd highlight two important items that Sameer mentioned. To start, we saw real demand expansion in Q2 of about 20%, despite the fact that growth from Q1 to Q2 came in at something like 36%. Inventory accounted for the remainder. From Q2 to Q3, three of four regions averaged 21% growth. That's quite strong. That makes two quarters running moving along at 20%. Now, one region did trail behind owing to certain staffing problems and turnover problems that arose in Q3, but as Sameer described, we believe we have a fairly solid grip on that. Obviously, if we kept going at 20% each quarter at this pace, we'd hit the target range, $150 million-$200 million, well before mid-2028. In my view, we're actually exceeding expectations at the moment. Exactly when that kind of curve takes hold is hard to pin down. I'd add as well, though, that Sameer provided quite clear guidance regarding his plans to get us there and why converting the community depends on educating the community. That's truly where our attention is. We've observed that when these physicians are introduced to the clinical data, when they recognize the meaningful benefit of LOQTORZI when it comes to survival for these patients, they convert readily; it's simply a question of reach and the converts. Again, that's why we find that after these physicians try LOQTORZI, they return to it with a subsequent patient. Glad to take your follow-up.
Yeah, and turning to the colorectal side now. I'm just wondering how you're viewing the benchmark. When we consider the data. Colorectal comes later next year, and in the fourth line setting that's a pretty late line. What should we be thinking in terms of a benchmark at that point? And then, sort of pulling back, when you look at 114 as. Taken as a whole, there are several data reads arriving across a range of indications. Do you have any sense of how you'd end up prioritizing indications. Given that you do have a number of multiple. The amount of data readouts that are coming? Thank you.
All right. I'll address the first one initially and then pass it over to Dr. Dias. To begin with, we believe that, as we mentioned during our prepared remarks, we believe that the Nobel Prize for Physiology and Medicine, acknowledging the significance of T regulatory cells, is truly, truly something worth noting. We plan to demonstrate scientific leadership and remain at the forefront of this, and that's what we've done. I'll simply remind you of what we said regarding the SITC webinar and such that Dr. Dias took part in; we felt driven to enter colorectal, where first-line colorectal is chemotherapy, the same treatment for 20 years; this is a disease that hits increasingly younger patients and is truly, truly critical. I think we hold the view that it's truly deserving of thorough investigation. As for your particular questions about colorectal, Rosh, would you like to offer some observations?
Yes, absolutely. Thank you, Brian, for asking. Regarding your first question about what benchmarks we should use for colorectal, let me lay out a few things. To start, as Denny said, colorectal represents a big indication, and it's expanding, especially among younger people. Right now, this is a space where there's genuine opportunity to do better for patients when it comes to possible gains in the standard of care. For the fourth line plus group, the overall response rate sits in the mid-single digits at present. Chemotherapy is what's typically used as standard of care, and that's again roughly 5%-6% when it comes to overall response rate. Our approach is to examine the totality of evidence, so naturally we'd aim to surpass that on overall response rate. Beyond that, durability matters. Disease stability matters. As you consider the full totality of evidence, many different factors carry weight. I'm genuinely enthusiastic about what the Tori CCR8 combination could do in late line. Clearly, the intention is to advance into earlier lines after that.
Brian, I’ll address your question about the way we’d rank these indications, and I’ll invite others on my team to add their thoughts. To begin with, we believe there is solid clinical rationale as well as a solid rationale based on mechanism of action for each of them. You can spot the situations where Tregs pose a problem, and those are precisely the cancers we are targeting. As for gastric cancer, I’d remind you that meaningful efficacy has consistently been demonstrated against a backdrop of toripalimab in other groups’ experience; in our view, the likelihood of success there is quite high, and it represents a very meaningful indication. Turning to esophageal cancer, that is a setting in which toripalimab has in fact demonstrated activity in low PD-1 states, and where it holds approval in Europe, for instance. That is a place where, although the indication is not a large one, we have considerable interest in pursuing additional study. With respect to head and neck cancer, I believe you already know the data we have presented, including the partial response and similar findings. We consider those results strong. Honestly, we would likely pursue other indications using our CHS-114, yet we believe we now have these highly encouraging ones. I’d simply ask, Theresa, whether you have anything to add regarding how we choose indications or the kinds of things we might target next?
Right. So I'd say we've now profiled quite a few solid tumors where CCR8-positive Tregs show up at high density and high prevalence. What I mean is tumor types we aren't currently targeting that would still be worth pursuing. There have been a few signs of activity in rival programs, in lung cancer and breast cancer. Following the share, we saw data in pancreatic cancer. The way our program is built is to tell us the optimal setting where the biggest effect shows up. Is that density of CCR8-positive Tregs? Is that the percentage of CCR8-positive Tregs? Or is it some ratio involving the T cells? What our program is set up to do next year is read out some key information on the best way to approach rapid development, and then development, so we can combine with other agents and achieve wider efficacy across several tumor types.
One more thing I'd mention: in our view, this initiative of ours is wide-ranging, covering plenty of these indications adequately, yet at the same time it's very focused, correct? Ultimately, I believe that will prove quite advantageous for us. Thanks, Brian.
Thanks a lot. Yes, I appreciate it, Denny and everyone, and I’m eager for the data read next year. Thank you.
So are we.
Hey there. So, regarding casdozo, what data from the phase two would you require before deciding to go directly into a pivotal trial?
Appreciate that, Jason. Dr. Dias, do you want to address that?
Yes, of course. Jason, I appreciate that question. A key point to keep in mind—and I mentioned this before—is that our approach involves examining all the available evidence together, rather than relying on just one individual metric. The results for Atizo-Bev-Casdozokitug that we shared earlier this year have given us a great deal of optimism. Let me remind everyone once more: what we observed was early findings, followed by a higher response rate and a response that grew deeper as time went on. Looking ahead to next year, when we release our data during the first half of the year—at least the preliminary findings—we hope to observe a strong response rate overall. We hope to observe some durability there. We hope to observe really favorable durability regarding how long some of those effects persist, and then a rise over time in the response rate itself, plus. A full deepening of the responses too. Those, in my view, are among the crucial metrics, but truly, I want to stress that what matters is the complete body of evidence, not merely one or two individual measures.
Thanks, Jason.
All right, thank you.
Hi, Nick here stepping in for calling. Appreciate you fielding our question. Could you assist in putting a number on how much longer patients are staying on LOQTORZI, which you're currently observing? What do you believe is behind that lengthening, and do you see potential for further expansion there? I'll have another question once that's answered. Thanks.
My apologies, Nick. Which specific indication were you thinking about?
My apologies — that was regarding the commercial side of NPC.
Ah, excellent. Sameer, would you like to discuss that?
Right, absolutely. Thanks a lot for that question, Nick. The length of time patients stay on therapy keeps going up. Quarter over quarter, we observe that treatment duration is rising; we still haven't reached the mean treatment duration recorded in the clinical trials, though the reason for that is simply that we've not been in the market long enough to hit that mean. It's a bit too soon after launch for us to provide a precise figure for treatment duration, yet in both the monotherapy indication and the combination therapy indication, with each passing quarter, we're seeing a positive rise in the average duration. Once we have data allowing us to state with confidence what the average on-market duration is, we'll share that on a future call.
Nick, was there something else you wanted to ask?
Yes, I did. Thanks. Regarding the CHS-114 tori study in second-line head and neck, could you talk about what you expect when the dose optimization data arrives in the first half of 2026 — what you hope to demonstrate — and after that, what comes next, what the next steps for that program would be? Thanks.
Great. Head and neck. Rosh.
Sure, of course. The trial we're running focuses on second line head and neck. Enrollment is 40 patients, with a couple of biologically active dose levels of casdozokitug combined with toripalimab. As I mentioned before, recruitment is going well and according to plan, and we expect to have efficacy and safety data during the first half of the year. Looking at the whole picture of evidence matters. Right now, at least, for the current standard of care in second line with cetuximab, the overall response rate is approximately 13%, which, again, is the current standard of care. We'd like to substantially exceed that; we also want to see durability, correct? We want to observe durability, disease stability, and so on. I think seeing some of the results we shared at AACR really gives us encouragement as we consider what we... as we continue moving forward in this ongoing trial.
The biopsy information is also a key result from that trial, along with the dose needed to reach a recommended phase two dose. We had a highly productive type D meeting with the FDA, where we gained alignment on the data package we'll present to them next year in order to declare a recommended phase two dose. That will let us move more nimbly and have one dose to examine across multiple indications.
Thank you, Theresa.
Thanks, Nick.
Thanks.
Hello, and good evening. I appreciate your time on this call. Denny, I suppose I'll focus on the colorectal trial. I'm just attempting to grasp the underlying reasoning. I believe, Rosh, you brought up that the focus is the fourth-line context, where survival figures are in the single digits. And from where you sit, what do you anticipate when it comes to identifying a truly strong signal in a group of patients who are already this ill?
Doug, I appreciate that question. Allow me to share this observation. To begin with, moving into the fourth-line setting fits within a broader development strategy that, as time goes on, shifts us considerably earlier in the treatment paradigm. I believe our approach is highly efficient and thoughtfully designed, and we can discuss that at a later point. As for what you specifically asked, I'll have Dr. LaVallee address a couple of items. To start, the mechanism of action along with the rationale, especially in CRC, for CHS-114, or Treg depleters. And next, the way favorable data from that trial will position us for trials down the road. Theresa.
Right. The value of the 114 clinical program ties back to my opening point — it's genuinely built to teach us something. Colorectal matters as a tumor type for a few reasons: there's solid density and prevalence of CCR8-positive Tregs there. Alexander Rudensky, who is among the true pioneers in Tregs and CCR8 biology, has put out multiple papers on Treg diversity and differentiation, especially in the colon, demonstrating that the pathogenic ones are indeed the CCR8-positive Tregs; that gives a stronger feeling that this tissue's tumor ought to be especially responsive. Colorectal has not. MSS colorectal. From the microsatellite stable populations, we understand a PD-1 inhibitor is able to work in this disease given the right context. 85%-90% of colon cancer is MSS, microsatellite stable CRC, where PD-1 inhibitors have failed. A big part of that comes down to the high density and prevalence of Tregs. So given the biology, colorectal is especially exciting. Shionogi, using a CCR8 antibody lacking ADCC enhancement, reported a complete response and partial response from single-agent treatment at ASCO this year. In our early clinical program, we've observed some long-term stable disease. So that signed deal, alongside toripalimab, truly creates an exciting opportunity to deliver immunotherapy to a tumor type that has had none. The totality of data — preclinical, clinical, and the target's biology — gives it a very important attribute. As Denny said, the other things under test are the highest density of CCR8-positive in gastric cancer and head and neck cancer. And then esophageal, which differs somewhat because toripalimab has differentiated activity and an approval in Europe. Strategically, I think the entire program hands us many levers for examining how to pursue the fastest development with the greatest impact to move the program forward.
Thanks, Theresa. Doug, I want to express appreciation to Dorothy as well, and mention how privileged we feel that Dr. Alexander Rudensky serves as an essential member of our scientific advisory board, since he truly stands among the foundational pioneers in the whole area of Tregs, which has recently gained prominence. In my view, he deserves credit for a substantial share of our scientific direction in this domain, and as I noted during my prepared remarks, we anticipate carrying that forward through 2026.
All right, that's wonderful. I really appreciate it.
Thanks, Doug.
Appreciate that, Heidi. Thanks to everyone for being with us this afternoon on the Coherus Oncology Q3 call. One more thing from me: we'll be present at the UBS conference out in sunny West Palm Beach, Florida. Jefferies in London is on our schedule as well, and we're hoping to see you there. Thanks. Bye-bye.
This concludes today's conference. Goodbye. Thank you for participating. You may now disconnect.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete Coherus Oncology, Inc. transcript - plus 132,000+ transcripts from 7,000+ companies, speaker segments and full-text search - through the EarningsAPI REST API or hosted MCP server.
Get an API key View API docs →For developers and AI pipelines
Programmatic access to Coherus Oncology, Inc. earnings transcripts and 132,000+ others is available through the
EarningsAPI REST API and the hosted MCP server.
Quarterly plans from $162 - full transcripts, speaker segments, full-text search,
and the /api/v1/transcripts/recent polling endpoint for ETL pipelines.